A Direct ROI Quantification Method for Inherent PVE Correction: Accuracy Assessment in Striatal SPECT Measurements

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2007 Mar 29

PMID 17390134

Citations 7

Authors

Eleonora Vanzi

Maria Teresa De Cristofaro

Silvia Ramat

Barbara Sotgia

Mario Mascalchi

Andreas Robert Formiconi

Affiliations

Soon will be listed here.

Abstract

Purpose: The clinical potential of striatal imaging with dopamine transporter (DAT) SPECT tracers is hampered by the limited capability to recover activity concentration ratios due to partial volume effects (PVE). We evaluated the accuracy of a least squares method that allows retrieval of activity in regions of interest directly from projections (LS-ROI).

Methods: An Alderson striatal phantom was filled with striatal to background ratios of 6:1, 9:1 and 28:1; the striatal and background ROIs were drawn on a coregistered X-ray CT of the phantom. The activity ratios of these ROIs were derived both with the LS-ROI method and with conventional SPECT EM reconstruction (EM-SPECT). Moreover, the two methods were compared in seven patients with motor symptoms who were examined with N-3-fluoropropyl-2-beta-carboxymethoxy-3-beta-(4-iodophenyl) (FP-CIT) SPECT, calculating the binding potential (BP).

Results: In the phantom study, the activity ratios obtained with EM-SPECT were 3.5, 5.3 and 17.0, respectively, whereas the LS-ROI method resulted in ratios of 6.2, 9.0 and 27.3, respectively. With the LS-ROI method, the BP in the seven patients was approximately 60% higher than with EM-SPECT; a linear correlation between the LS-ROI and the EM estimates was found (r=0.98, p=0.03).

Conclusion: The LS-ROI PVE correction capability is mainly due to the fact that the ill-conditioning of the LS-ROI approach is lower than that of the EM-SPECT one. The LS-ROI seems to be feasible and accurate in the examination of the dopaminergic system. This approach can be fruitful in monitoring of disease progression and in clinical trials of dopaminergic drugs.

Citing Articles

An energy-optimized collimator design for a CZT-based SPECT camera.

Weng F, Bagchi S, Zan Y, Huang Q, Seo Y Nucl Instrum Methods Phys Res A. 2015; 806:330-339.

PMID: 26640308 PMC: 4665111. DOI: 10.1016/j.nima.2015.09.115.

Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy.

Sciagra R, Passeri A, Cipollini F, Castagnoli H, Olivotto I, Burger C Eur J Nucl Med Mol Imaging. 2015; 42(10):1581-8.

PMID: 26121929 DOI: 10.1007/s00259-015-3101-y.

Improved regional activity quantitation in nuclear medicine using a new approach to correct for tissue partial volume and spillover effects.

Moore S, Southekal S, Park M, McQuaid S, Kijewski M, Muller S IEEE Trans Med Imaging. 2011; 31(2):405-16.

PMID: 21965196 PMC: 3741650. DOI: 10.1109/TMI.2011.2169981.

Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease.

Berti V, Polito C, Ramat S, Vanzi E, De Cristofaro M, Pellicano G Eur J Nucl Med Mol Imaging. 2009; 37(3):537-44.

PMID: 19727712 DOI: 10.1007/s00259-009-1259-x.

Clinical correlation of the binding potential with 123I-FP-CIT in de novo idiopathic Parkinson's disease patients.

Berti V, Pupi A, Ramat S, Vanzi E, De Cristofaro M, Pellicano G Eur J Nucl Med Mol Imaging. 2008; 35(12):2220-6.

PMID: 18649079 DOI: 10.1007/s00259-008-0872-4.

References

Chaly T, Dhawan V, Kazumata K, Antonini A, Margouleff C, DAHL J . Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography. Nucl Med Biol. 1996; 23(8):999-1004. DOI: 10.1016/s0969-8051(96)00155-2. View

Cooke B, Evans A . A phantom to assess quantitative recovery of positron tomographs. J Comput Assist Tomogr. 1983; 7(5):876-80. DOI: 10.1097/00004728-198310000-00023. View

Minoshima S, Koeppe R, Frey K, Kuhl D . Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med. 1994; 35(9):1528-37. View

Soret M, Koulibaly P, Darcourt J, Hapdey S, Buvat I . Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT. J Nucl Med. 2003; 44(7):1184-93. View

Huesman R . A new fast algorithm for the evaluation of regions of interest and statistical uncertainty in computed tomography. Phys Med Biol. 1984; 29(5):543-52. DOI: 10.1088/0031-9155/29/5/007. View

Chen C, Muzic Jr R, Nelson A, Adler L . Simultaneous recovery of size and radioactivity concentration of small spheroids with PET data. J Nucl Med. 1999; 40(1):118-30. View

Innis R, Seibyl J, Scanley B, Laruelle M, Abi-Dargham A, Wallace E . Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A. 1993; 90(24):11965-9. PMC: 48106. DOI: 10.1073/pnas.90.24.11965. View

Cot A, Falcon C, Crespo C, Sempau J, Pareto D, Bullich S . Absolute quantification in dopaminergic neurotransmission SPECT using a Monte Carlo-based scatter correction and fully 3-dimensional reconstruction. J Nucl Med. 2005; 46(9):1497-504. View

Du Y, Tsui B, Frey E . Partial volume effect compensation for quantitative brain SPECT imaging. IEEE Trans Med Imaging. 2005; 24(8):969-76. DOI: 10.1109/TMI.2005.850547. View

10.

Kojima A, Matsumoto M, Takahashi M, Hirota Y, Yoshida H . Effect of spatial resolution on SPECT quantification values. J Nucl Med. 1989; 30(4):508-14. View

11.

Hashimoto J, Sasaki T, Ogawa K, Kubo A, Motomura N, Ichihara T . Effects of scatter and attenuation correction on quantitative analysis of beta-CIT brain SPET. Nucl Med Commun. 1999; 20(2):159-65. DOI: 10.1097/00006231-199902000-00008. View

12.

Acton P, Newberg A, Plossl K, Mozley P . Comparison of region-of-interest analysis and human observers in the diagnosis of Parkinson's disease using [99mTc]TRODAT-1 and SPECT. Phys Med Biol. 2006; 51(3):575-85. DOI: 10.1088/0031-9155/51/3/007. View

13.

Rorden C, Brett M . Stereotaxic display of brain lesions. Behav Neurol. 2001; 12(4):191-200. DOI: 10.1155/2000/421719. View

14.

Rousset O, Ma Y, Evans A . Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998; 39(5):904-11. View

15.

Meltzer C, Zubieta J, Links J, Brakeman P, Stumpf M, Frost J . MR-based correction of brain PET measurements for heterogeneous gray matter radioactivity distribution. J Cereb Blood Flow Metab. 1996; 16(4):650-8. DOI: 10.1097/00004647-199607000-00016. View

16.

da Silva A, Tang H, Wong K, Wu M, Dae M, Hasegawa B . Absolute quantification of regional myocardial uptake of 99mTc-sestamibi with SPECT: experimental validation in a porcine model. J Nucl Med. 2001; 42(5):772-9. View

17.

Carson R . A maximum likelihood method for region-of-interest evaluation in emission tomography. J Comput Assist Tomogr. 1986; 10(4):654-63. DOI: 10.1097/00004728-198607000-00021. View

18.

Quarantelli M, Berkouk K, Prinster A, Landeau B, Svarer C, Balkay L . Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J Nucl Med. 2004; 45(2):192-201. View

19.

Links J, Prince J, Bryan R, McVeigh E, Leal J, Davatzikos C . Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab. 1992; 12(4):571-83. DOI: 10.1038/jcbfm.1992.81. View

20.

Meyer P, Sattler B, Lincke T, Seese A, Sabri O . Investigating dopaminergic neurotransmission with 123I-FP-CIT SPECT: comparability of modern SPECT systems. J Nucl Med. 2003; 44(5):839-45. View